Kyowa Kakko Kirin signs license agreement of hyperphosphatemia treatment ‘Nephoxil’

Published: 2017-02-28 14:25:21

Updated: 2017-02-28 14:25:21

Kyowa Hakko Kirin Korea(CEO Shigeaki Suzuki) announced a license agreement of the hyperphosphatemia treatment ‘Nephoxil’ with Taiwanese Panion & BF Biotech on the 20^th of February.

Hyperphosphatemia is a symptom in which there is an abnormally elevated level of phosphate in the blood for chronic renal failure patients or dialysis patients, which may cause hyperparathyroidism and renal osteodys...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.